Table 1.
Study | Sample size | Exposure 1 | Immune analysis | Exposure 2 | Immune analysis | Exposure 3 | Immune analysis |
---|---|---|---|---|---|---|---|
A | 29 | 2 × 109 CFU EcSf2a-2 | Post vaccination | 1 × 103 CFU 2457T | Post challenge | ||
B | 11 | 7 × 108 CFU EcSf2a-2 | Post vaccination | 1 × 103 CFU 2457T | Post challenge | ||
B | 8 | Placebo | 1 × 103 CFU 2457T | Post challenge | |||
B+C | 5 | 7 × 108 CFU EcSf2a-2 | Post vaccination | 1 × 103 CFU 2457T | Post challenge | 1.4 × 103 CFU 2457T | Post challenge |
B+C | 6 | Placebo | 1 × 103 CFU 2457T | Post challenge and post “vaccination” | 1.4 × 103 CFU 2457T | Post challenge | |
C | 12 | 1.4 × 103 CFU 2457T | Post challenge | ||||
C | 7 | 1.4 × 102 CFU 2457T | Post challenge |